Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic

The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.